AIDS News and Research RSS Feed - AIDS News and Research

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. [More]
MiMedx Group reports record revenue of $118.2 million for full year 2014

MiMedx Group reports record revenue of $118.2 million for full year 2014

MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for the fourth quarter and full year ended December 31, 2014. [More]
Three innovative research projects aim to improve lives of people with mobility difficulties

Three innovative research projects aim to improve lives of people with mobility difficulties

A prosthetic hand controlled by the nervous system, robotic clothing to help people with walking, and biosensors to monitor how patients use equipment or exercise during rehabilitation are the focus of three research projects awarded £5.3 million by the Engineering and Physical Sciences Research Council. [More]
MPP, MSD sign licensing agreement for paediatric formulations of raltegravir

MPP, MSD sign licensing agreement for paediatric formulations of raltegravir

The Medicines Patent Pool announced a licence today with MSD, known as Merck in the United States and Canada, for paediatric formulations of raltegravir, a key medicine approved for children living with HIV four weeks of age and older. [More]
Mylan to distribute Sovaldi and Harvoni tablets in India for treatment of chronic hepatitis C

Mylan to distribute Sovaldi and Harvoni tablets in India for treatment of chronic hepatitis C

Mylan Inc. today announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, has entered into an agreement with Gilead Sciences, under which Mylan has been appointed as the exclusive distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni (ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, in India. [More]

Hiroshima University develops Sensorimotor Enhancing Suit to support human motion

A prototype for wearable equipment to support human motion has been developed at Hiroshima University, Japan. This wearable equipment, called the Sensorimotor Enhancing Suit (SEnS), enhances sensorimotor functions by reducing the muscle load of the upper limbs. [More]
Case Western dental researcher discovers new way to model how T cells cause inflammation in mice

Case Western dental researcher discovers new way to model how T cells cause inflammation in mice

Case Western Reserve University dental researcher Pushpa Pandiyan has discovered a new way to model how infection-fighting T cells cause inflammation in mice. [More]
Researchers review ten years of scientific studies on mitochondrial toxicity in pregnant women

Researchers review ten years of scientific studies on mitochondrial toxicity in pregnant women

Researchers from the Hospital Clinic of Barcelona (Spain) have reviewed ten years' worth of scientific studies on mitochondrial toxicity in pregnant women. Exposure to toxic agents such as viruses, certain drugs, pesticides, alcohol and tobacco cause mitochondrial diseases about which very little is known, and which are transmitted from the mother to the foetus. [More]
Scientists develop promising new HIV vaccine agent

Scientists develop promising new HIV vaccine agent

In a study that involved researchers from over a dozen institutions, the anti-HIV agent protected monkeys from every strain of HIV-1, HIV-2 and SIV (simian immunodeficiency virus) for at least 34 weeks. [More]
Einstein researchers find possible clue to why older mothers have babies born with Down syndrome

Einstein researchers find possible clue to why older mothers have babies born with Down syndrome

Researchers at Albert Einstein College of Medicine of Yeshiva University have found a possible clue to why older mothers face a higher risk for having babies born with conditions such as Down syndrome that are characterized by abnormal chromosome numbers. [More]
Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

A drug used to treat patients with Crohn's disease and multiple sclerosis has helped scientists confirm how "viral reservoirs" form in patients living with HIV and also proven effective in animal trials at blocking the pathways to those reservoirs in the brain and gut, a team of researchers reported recently in the journal PLOS Pathogens. [More]
New clinical trial launched in South Africa to study investigational HIV vaccine regimen

New clinical trial launched in South Africa to study investigational HIV vaccine regimen

A clinical trial called HVTN 100 has been launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in study participants. This experimental vaccine regimen is based on the one tested in the U.S. Military HIV Research Program-led RV144 clinical trial in Thailand--the first study to demonstrate that a vaccine can protect people from HIV infection. [More]
San Francisco AIDS Foundation unveils new mobile testing unit

San Francisco AIDS Foundation unveils new mobile testing unit

On Valentine's Day, San Francisco AIDS Foundation unveiled a new mobile testing unit, an essential element in the plan to eliminate HIV transmission in San Francisco. The new unit—a 33-foot-long vehicle outfitted specifically for HIV and STI testing—will increase the availability of free testing in neighborhoods across the city at times when other HIV testing sites are closed. [More]
TSRI scientists develop new drug candidate against HIV

TSRI scientists develop new drug candidate against HIV

In a remarkable new advance against the virus that causes AIDS, scientists from the Jupiter, Florida campus of The Scripps Research Institute have announced the creation of a novel drug candidate that is so potent and universally effective, it might work as part of an unconventional vaccine. [More]
Women who understand risks associated with mammography screening make better screening choices

Women who understand risks associated with mammography screening make better screening choices

Women who understand the risk of over-detection and over-diagnosis associated with mammography screening have lower intentions to have a breast screening test, according to a new Lancet study. [More]
UNICEF and UNAIDS go ‘All In’ to end the AIDS epidemic among adolescents

UNICEF and UNAIDS go ‘All In’ to end the AIDS epidemic among adolescents

AIDS has become the second leading cause of death among adolescents globally. Just one in four children and adolescents under the age of 15 have access to life-saving antiretroviral treatment. Deaths are declining in all age groups, except among 10–19 year olds. [More]
Report: Proposed SDGs may not achieve policy objectives without clearer, more measurable targets

Report: Proposed SDGs may not achieve policy objectives without clearer, more measurable targets

The proposed UN Sustainable Development Goals (SDGs) - a universal set of goals to guide international development to 2030 - will struggle to achieve their stated policy objectives without clearer, more measurable targets, according to a new report released today by the International Council for Science and the International Social Science Council. [More]
KU Leuven researchers find aggressive form of HIV in Cuba

KU Leuven researchers find aggressive form of HIV in Cuba

Engaging in unprotected sex with multiple partners increases the risk of contracting multiple strains of HIV, the virus that causes AIDS. Once inside a host, these strains can recombine into a new variant of the virus. One such recombinant variant observed in patients in Cuba appears to be much more aggressive than other known forms of HIV. [More]
Study evaluates recent sleep trends for U.S. adolescents

Study evaluates recent sleep trends for U.S. adolescents

Sufficient sleep is critical for adolescent health, yet the number of hours slept per night has decreased among teenagers in the United States over the last 20 years. A study by researchers at Columbia University's Mailman School of Public Health found that female students, racial/ethnic minorities, and students of lower socioeconomic status are particularly affected, with teens in these categories less likely to report regularly getting seven or more hours of sleep each night compared with their male counterparts, non-Hispanic white teenagers, and students of higher socioeconomic status, respectively. [More]
New electronic model holds promise of revolutionizing shared decision-making in doctor's office

New electronic model holds promise of revolutionizing shared decision-making in doctor's office

Traditional decision aids to help patient-doctor discussions have drawbacks, but a new electronic model developed by McMaster University researchers holds promise of revolutionizing shared decision-making in the doctor's office with the touch of an electronic tablet. [More]